Diethylcarbamazine warnings and precautions: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi (talk | contribs) Created page with "__NOTOC__ {{Diethylcarbamazine}} {{CMG}} <ref>{{Cite web | last = | first = | title = WHO Model Prescribing Information: Drugs Used in Parasitic Diseases - Second Editi..." |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}} | {{CMG}} | ||
==Warnings and Precautions== | |||
Dosage should be reduced in patients with renal impairment. | |||
Patients who are severely ill with other acute diseases should not receive diethylcarbamazine until after their recovery. | |||
<ref>{{Cite web | last = | first = | title = WHO Model Prescribing Information: Drugs Used in Parasitic Diseases - Second Edition: Helminths: Lymphatic filariasis: Diethylcarbamazine | url = http://apps.who.int/medicinedocs/en/d/Jh2922e/3.5.1.html#Jh2922e.3.5.1 | publisher = | date = | accessdate = }}</ref> | Pregnant women should not be treated until after delivery.<ref>{{Cite web | last = | first = | title = WHO Model Prescribing Information: Drugs Used in Parasitic Diseases - Second Edition: Helminths: Lymphatic filariasis: Diethylcarbamazine | url = http://apps.who.int/medicinedocs/en/d/Jh2922e/3.5.1.html#Jh2922e.3.5.1 | publisher = | date = | accessdate = }}</ref> | ||
==References== | ==References== | ||
Latest revision as of 02:13, 7 January 2014
| Diethylcarbamazine |
|---|
| HETRAZAN® WHO Prescribing Information |
| Description |
| Indications and Usage |
| Contraindications |
| Warnings and Precautions |
| Adverse Reactions |
| Overdosage |
| Dosage and Administration |
| How Supplied |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Warnings and Precautions
Dosage should be reduced in patients with renal impairment.
Patients who are severely ill with other acute diseases should not receive diethylcarbamazine until after their recovery.
Pregnant women should not be treated until after delivery.[1]
References
Adapted from the FDA Package Insert.